LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli‐Ann Monaco, Giordano Caponigro|Clinical Cancer Research|2020Cited by 87